GLP-1 Drugs Linked to 30% Higher Osteoporosis Risk After 5 Years

The AAOS study highlights the importance of monitoring bone density during long-term GLP-1 therapy.

As GLP-1 medications are prescribed to millions of patients for weight care and diabetes, researchers are tracking their long-term effects on skeletal health. A retrospective study presented at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting highlights an important safety trend. Analyzing records of over 140,000 patients, researchers found that five years of continuous GLP-1 use is associated with a 30% higher risk of developing osteoporosis.

This finding has sparked a lively debate among doctors. Medical experts are trying to determine if the bone density loss is a direct side effect of the drugs or a natural consequence of losing weight rapidly.

Details of the 140,000-Patient AAOS Cohort Study

The study, conducted with Epic Research, evaluated 143,200 adult patients continuously prescribed GLP-1 medications like semaglutide and tirzepatide for at least five years. Researchers compared them to a matched control group taking other metabolic therapies. Over the five-year window, the GLP-1 group showed a significant increase in new osteoporosis diagnoses.

The risk was highest in postmenopausal women and older men, groups already prone to bone loss. However, younger patients who lost weight rapidly in the first 18 months also showed elevated risk. This has led to calls for clinical guidelines on monitoring bone health during long-term weight care.

Increased Rates of Gout and Tendon Injuries

The AAOS presentation also revealed other orthopaedic concerns among patients experiencing rapid weight loss. Specifically, the study documented a 24% increase in gout flares and a 15% increase in tendon injuries (such as rotator cuff and Achilles tendon issues). Gout flares typically occurred during the active weight loss phase:

• Rapid breakdown of fat can temporarily alter uric acid levels, triggering painful gout flares in susceptible patients.
• Tendon injuries may stem from changing biomechanics, as joints and muscles adapt to supporting a lighter body weight.
• Obesity specialists advise patients to introduce exercise gradually to give their joints time to adapt to their new proportions.

The Weight Loss vs. Drug Toxicity Debate

Doctors are divided on whether GLP-1 drugs directly harm bone cells or if the bone loss is simply a natural reaction to weighing less. Bone is a living tissue that adapts to weight; when you lose weight, the skeletal system experiences less mechanical load and naturally thins out. Many endocrinologists believe this mechanical offloading is the primary driver of the 30% risk increase.

However, laboratory research shows that GLP-1 receptors are present on bone-forming and bone-dissolving cells. This indicates that the drugs might directly influence how bone is remodeled. More clinical trials using bone scans are needed to resolve this debate and help clinicians protect patient bone density.

Clinical Guidelines for Monitoring Bone Health

To safeguard skeletal health, doctors are updating their metabolic care protocols. Experts recommend getting a baseline DEXA scan (a quick, painless bone density test) before starting long-term GLP-1 therapy, followed by checks every two to three years. This is especially important for patients with existing risk factors like postmenopausal status or smoking.

Additionally, patients should ensure they get enough calcium (1,000 to 1,200 mg daily) and Vitamin D (800 to 1,000 IU) from diet or supplements. Incorporating regular strength training is also vital, as weight-bearing exercises stimulate bone growth and help preserve muscle mass. If you are starting weight care, you can check their clinical eligibility or review metabolic program packages online.

Balancing Risks and Benefits in Metabolic Care

While a 30% relative risk increase in osteoporosis warrants attention, experts emphasize that the massive benefits of GLP-1s outweigh these risks for most patients. Landmark trials show that these therapies reduce the risk of major heart attacks and strokes by 15% to 20%. For patients with severe obesity or diabetes, these cardiovascular benefits are life-saving.

Proactive bone management is the key to balancing these risks. By combining GLP-1 treatments with strength training, proper nutrition, and routine bone density scans, patients can achieve metabolic success while keeping their bones strong. Your healthcare provider can help customize a plan that protects your long-term mobility.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.